Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Profit After Tax (2021 - 2025)

Historic Profit After Tax for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$12.9 million.

  • ProQR Therapeutics' Profit After Tax fell 4449.79% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 8137.66%. This contributed to the annual value of -$30.0 million for FY2024, which is 15.84% down from last year.
  • Per ProQR Therapeutics' latest filing, its Profit After Tax stood at -$12.9 million for Q3 2025, which was down 4449.79% from -$13.8 million recorded in Q2 2025.
  • ProQR Therapeutics' 5-year Profit After Tax high stood at $19.0 million for Q2 2021, and its period low was -$23.5 million during Q3 2022.
  • In the last 5 years, ProQR Therapeutics' Profit After Tax had a median value of -$9.5 million in 2023 and averaged -$7.0 million.
  • In the last 5 years, ProQR Therapeutics' Profit After Tax soared by 7488.95% in 2023 and then tumbled by 37555.1% in 2025.
  • Over the past 5 years, ProQR Therapeutics' Profit After Tax (Quarter) stood at -$20.9 million in 2021, then soared by 34.97% to -$13.6 million in 2022, then surged by 56.52% to -$5.9 million in 2023, then tumbled by 68.55% to -$9.9 million in 2024, then decreased by 29.4% to -$12.9 million in 2025.
  • Its last three reported values are -$12.9 million in Q3 2025, -$13.8 million for Q2 2025, and -$10.6 million during Q1 2025.